INT157048

Context Info Confidence 0.18 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 0.31 Pain Relevance 2.73

peptidase activity (Mcpt1) extracellular region (Mcpt1) intracellular (Mcpt1)

Anatomy Link Frequency microglia 2 Mcpt1 (Mus musculus)

Pain Link Frequency Relevance Heat cytokine 85 99.24 tetrodotoxin 7 98.64 Inflammation 46 97.20 Morphine 78 90.04 sodium channel 8 84.76 Nav1.9 1 84.12 nav1.8 1 83.64 Nav1.7 1 83.32 nav1.3 1 83.00 adenocard 1 82.88

Disease Link Frequency Relevance Heat INFLAMMATION 52 97.20 Acquired Immune Deficiency Syndrome Or Hiv Infection 32 50.00 Diabetes Mellitus 29 50.00 Insulin Resistance 8 50.00 Impaired Glucose Tolerance 6 50.00 Hyperlipidemia 2 50.00 Obesity 33 27.76 Metabolic Disorder 6 5.00 Body Weight 3 5.00 Drug Dependence 2 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

On the other hand, Rx had a more effective inhibitory effect than Rosiglitazone on the secretion of MCP-1 and IL-6 (figure 3a, b).

Regulation (effect) of Localization (secretion) of MCP-1

1) Confidence 0.18 Published 2010 Journal Nutr Metab (Lond) Section Body Doc Link PMC2936435 Disease Relevance 0.31 Pain Relevance 0.24

Furthermore, the release of MCP-1 and IL-6 is highly calcium-dependent.

Regulation (dependent) of Localization (release) of MCP-1

2) Confidence 0.08 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2605563 Disease Relevance 0 Pain Relevance 0.82

Phenytoin attenuated by approximately 50% the release of IL-1 alpha, IL-1 beta, and TNF-alpha from LPS-stimulated microglia, but had minimal effects on the release of IL-2, IL-4, IL-6, IL-10, MCP-1, and TGF-alpha.

Regulation (effects) of Localization (release) of MCP-1 in microglia

3) Confidence 0.07 Published 2009 Journal Glia Section Abstract Doc Link 19115387 Disease Relevance 0 Pain Relevance 1.68

General Comments

This test has worked.